AYTU BioPharma
AYTU
50 hedge funds and large institutions have $26.1M invested in AYTU BioPharma in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 24 closing their positions.
70% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $808K
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
0.33% less ownership
Funds ownership: 1.36% → 1.03% (-0.33%)
22% less funds holding
Funds holding: 64 → 50 (-14)
46% less capital invested
Capital invested by funds: $48.3M → $26.1M (-$22.2M)
58% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.58M |
| 2 |
Renaissance Technologies
New York
|
+$2.03M |
| 3 |
VF
Virtu Financial
New York
|
+$597K |
| 4 |
D.E. Shaw & Co
New York
|
+$563K |
| 5 |
E
Ergoteles
New York
|
+$443K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$6.48M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.76M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$2.1M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$974K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$822K |
AYTU Hedge Fund Activity: Q2 2021 in Review
50 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q2 2021, worth a combined $26.1M — down 46% from $48.3M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of AYTU and 10 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 17 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $2.58M. The largest seller was BlackRock, cutting an estimated $6.48M.
- 50 institutional investors held AYTU BioPharma (AYTU) as of Q2 2021, down from 64 in Q1 2021.
- Funds reported $26.1M of AYTU BioPharma stock for Q2 2021, down 46% quarter-over-quarter.
- 10 funds opened new AYTU BioPharma positions in Q2 2021 and 24 closed out, a net change of -14 holders.
- The largest AYTU BioPharma buyer in Q2 2021 was Millennium Management, an estimated $2.58M added.
- The largest AYTU BioPharma seller in Q2 2021 was BlackRock, an estimated $6.48M sold.
Based on aggregated 13F filings for Q2 2021.